Update on rifampin, rifabutin, and rifapentine drug interactions

By Baciewicz Anne M.   Chrisman Cary R.   Finch Christopher K.   Self Timothy H.  

Current Medical Research and Opinion, Vol. 29, Iss. 1, 2013-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1012-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predicting Drug–Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 177-185

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolism‐related drug−drug interactions with tyrosine kinase inhibitors

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 2, 2015-02 ,pp. : 241-253

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic–pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units

By Hagihara Mao   Kasai Hidefumi   Umemura Takumi   Kato Takahiro   Hasegawa Takaaki   Mikamo Hiroshige  

Journal of Infection and Chemotherapy, Vol. 17, Iss. 2, 2011-04 ,pp. : 224-230

Springer Publishing Company

Access to resources Recommend Favorite